ECSP23029637A - Virus de la diarrea epidémica porcina atenuado - Google Patents
Virus de la diarrea epidémica porcina atenuadoInfo
- Publication number
- ECSP23029637A ECSP23029637A ECSENADI202329637A ECDI202329637A ECSP23029637A EC SP23029637 A ECSP23029637 A EC SP23029637A EC SENADI202329637 A ECSENADI202329637 A EC SENADI202329637A EC DI202329637 A ECDI202329637 A EC DI202329637A EC SP23029637 A ECSP23029637 A EC SP23029637A
- Authority
- EC
- Ecuador
- Prior art keywords
- diarrhea virus
- epidemic diarrhea
- attenuated swine
- swine epidemic
- virus
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20061—Methods of inactivation or attenuation
- C12N2770/20062—Methods of inactivation or attenuation by genetic engineering
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Pulmonology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
La divulgación proporciona una proteína espicular truncada en el terminal C de PEDV. También se proporcionan secuencias de ácidos nucleicos que la incluyen y un virus que la comprende, así como métodos de uso.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011048314.0A CN114315985A (zh) | 2020-09-29 | 2020-09-29 | 减毒猪流行性腹泻病毒 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP23029637A true ECSP23029637A (es) | 2023-07-31 |
Family
ID=78372132
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ECSENADI202329637A ECSP23029637A (es) | 2020-09-29 | 2023-04-24 | Virus de la diarrea epidémica porcina atenuado |
Country Status (15)
Country | Link |
---|---|
EP (1) | EP4221748A2 (es) |
JP (1) | JP2023543033A (es) |
KR (1) | KR20230079021A (es) |
CN (2) | CN114315985A (es) |
AR (1) | AR123646A1 (es) |
AU (1) | AU2021353430A1 (es) |
BR (1) | BR112023005715A2 (es) |
CA (1) | CA3197074A1 (es) |
CL (1) | CL2023000913A1 (es) |
CO (1) | CO2023004100A2 (es) |
EC (1) | ECSP23029637A (es) |
MX (1) | MX2023003651A (es) |
PE (1) | PE20240081A1 (es) |
TW (1) | TW202221012A (es) |
WO (1) | WO2022072215A2 (es) |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3137631A (en) | 1959-12-01 | 1964-06-16 | Faberge Inc | Encapsulation in natural products |
US3959457A (en) | 1970-06-05 | 1976-05-25 | Temple University | Microparticulate material and method of making such material |
US3914408A (en) | 1973-10-12 | 1975-10-21 | Univ Nebraska | Vaccine for neonatal calf diarrhea |
JPS5186117A (en) | 1975-01-27 | 1976-07-28 | Tanabe Seiyaku Co | Johoseibiryushiseizainoseiho |
US4205060A (en) | 1978-12-20 | 1980-05-27 | Pennwalt Corporation | Microcapsules containing medicament-polymer salt having a water-insoluble polymer sheath, their production and their use |
US4452747A (en) | 1982-03-22 | 1984-06-05 | Klaus Gersonde | Method of and arrangement for producing lipid vesicles |
US4744933A (en) | 1984-02-15 | 1988-05-17 | Massachusetts Institute Of Technology | Process for encapsulation and encapsulated active material system |
US5008050A (en) | 1984-06-20 | 1991-04-16 | The Liposome Company, Inc. | Extrusion technique for producing unilamellar vesicles |
US4921706A (en) | 1984-11-20 | 1990-05-01 | Massachusetts Institute Of Technology | Unilamellar lipid vesicles and method for their formation |
US4606940A (en) | 1984-12-21 | 1986-08-19 | The Ohio State University Research Foundation | Small particle formation and encapsulation |
US5084269A (en) | 1986-11-06 | 1992-01-28 | Kullenberg Fred W | Adjuvant for dose treatment with antigens |
US5009956A (en) | 1987-02-24 | 1991-04-23 | Univ Minnesota | Phospholipase A2-resistant liposomes |
US5504005A (en) | 1987-03-02 | 1996-04-02 | Albert Einstein College Of Medicine Of Yeshiva University | Recombinant mycobacterial vaccine |
JP3011939B2 (ja) | 1987-03-02 | 2000-02-21 | ホワイトヘツド・インスチチユート・フオー・バイオメデイカル・リサーチ | 組換えミコバクテリア・ワクチン |
US4927637A (en) | 1989-01-17 | 1990-05-22 | Liposome Technology, Inc. | Liposome extrusion method |
US4944948A (en) | 1989-02-24 | 1990-07-31 | Liposome Technology, Inc. | EGF/Liposome gel composition and method |
AU648505B2 (en) | 1989-05-19 | 1994-04-28 | Amgen, Inc. | Metalloproteinase inhibitor |
US5132117A (en) | 1990-01-11 | 1992-07-21 | Temple University | Aqueous core microcapsules and method for their preparation |
JPH05504067A (ja) | 1990-02-26 | 1993-07-01 | コモンウェルス サイエンティフィック アンド インダストリアル リサーチ オーガナイゼイション | 大腸菌及びマイコバクテリアのためのシャトルプラスミド |
GB9015888D0 (en) | 1990-07-19 | 1990-09-05 | Smithkline Biolog | Vectors |
CA2110682A1 (en) | 1991-06-06 | 1992-12-10 | Charles K. Stover | Induction of ctl responses to foreign antigens expressed in mycobacteria |
ATE235959T1 (de) | 1994-04-15 | 2003-04-15 | Univ Temple | Methode zum einkapseln mittels eines wässrigen lösungsmittels und mikrokapseln |
AU769539B2 (en) | 1999-01-29 | 2004-01-29 | Zoetis Services Llc | Adjuvants for use in vaccines |
CN1688606A (zh) | 2002-08-12 | 2005-10-26 | 昆士兰医学研究所理事会 | 含有辅助t细胞和b细胞表位的新的免疫原性脂肽 |
CN1688605B (zh) | 2002-08-12 | 2011-01-12 | 昆士兰医学研究所理事会 | 包含辅助t细胞和细胞毒性t淋巴细胞(ctl)表位的新免疫原性脂肽 |
WO2004026024A2 (en) | 2002-09-20 | 2004-04-01 | The United States Of America As Represented By The Secretary Of Agriculture | Vaccine compositions and adjuvant |
KR20080013850A (ko) | 2005-02-08 | 2008-02-13 | 더 카운실 오브 더 퀸즐랜드 인스티튜트 오브 메디컬 리서치 | 면역원성 분자 |
WO2007127936A2 (en) | 2006-04-27 | 2007-11-08 | Pikamab, Inc. | Methods and compositions for antibody therapy |
GB2552441A (en) * | 2015-10-22 | 2018-01-31 | Royal Veterinary College | Methods |
-
2020
- 2020-09-29 CN CN202011048314.0A patent/CN114315985A/zh active Pending
-
2021
- 2021-09-23 WO PCT/US2021/051807 patent/WO2022072215A2/en active Application Filing
- 2021-09-23 BR BR112023005715A patent/BR112023005715A2/pt unknown
- 2021-09-23 EP EP21798526.6A patent/EP4221748A2/en active Pending
- 2021-09-23 PE PE2023001249A patent/PE20240081A1/es unknown
- 2021-09-23 CN CN202180061801.7A patent/CN116635521A/zh active Pending
- 2021-09-23 JP JP2023519275A patent/JP2023543033A/ja active Pending
- 2021-09-23 KR KR1020237007715A patent/KR20230079021A/ko active Search and Examination
- 2021-09-23 AU AU2021353430A patent/AU2021353430A1/en active Pending
- 2021-09-23 MX MX2023003651A patent/MX2023003651A/es unknown
- 2021-09-23 CA CA3197074A patent/CA3197074A1/en active Pending
- 2021-09-27 TW TW110135848A patent/TW202221012A/zh unknown
- 2021-09-29 AR ARP210102711A patent/AR123646A1/es unknown
-
2023
- 2023-03-29 CO CONC2023/0004100A patent/CO2023004100A2/es unknown
- 2023-03-29 CL CL2023000913A patent/CL2023000913A1/es unknown
- 2023-04-24 EC ECSENADI202329637A patent/ECSP23029637A/es unknown
Also Published As
Publication number | Publication date |
---|---|
BR112023005715A2 (pt) | 2023-05-02 |
JP2023543033A (ja) | 2023-10-12 |
CO2023004100A2 (es) | 2023-04-05 |
CN114315985A (zh) | 2022-04-12 |
CL2023000913A1 (es) | 2023-11-24 |
EP4221748A2 (en) | 2023-08-09 |
PE20240081A1 (es) | 2024-01-16 |
AU2021353430A1 (en) | 2023-05-11 |
AR123646A1 (es) | 2022-12-28 |
MX2023003651A (es) | 2023-04-19 |
WO2022072215A2 (en) | 2022-04-07 |
TW202221012A (zh) | 2022-06-01 |
AU2021353430A9 (en) | 2024-01-18 |
WO2022072215A3 (en) | 2022-07-07 |
CN116635521A8 (zh) | 2023-11-03 |
CN116635521A (zh) | 2023-08-22 |
CA3197074A1 (en) | 2022-04-07 |
KR20230079021A (ko) | 2023-06-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2022001670A1 (es) | Inhibidores de proteínas kras mutantes | |
WO2022155530A8 (en) | Variant strain-based coronavirus vaccines | |
CY1121580T1 (el) | ΝΕΟΙ ΠΡΟΑΓΩΓΕΙΣ β-ΑΚΤΙΝΗΣ ΚΑΙ RPS21 ΚΑΙ ΧΡΗΣΕΙΣ ΑΥΤΩΝ | |
ECSP19034870A (es) | Péptidos escindibles y proteínas insecticidas y nematicidas que los comprenden | |
EA200700904A1 (ru) | Вакцины против вируса японского энцефалита и вируса западного нила | |
ATE497492T1 (de) | Reinigung von montelukast | |
AR067980A1 (es) | Peptidos de cdh3 y agentes que los comprenden | |
AR103672A1 (es) | Proteína resistente a los herbicidas, gen codificador y su uso | |
CY1113115T1 (el) | Πεπτιδια - αναστολεις συντηξης του ηiv με βελτιωμενες βιολογικες ιδιοτητες | |
EA201001045A1 (ru) | Модифицированный вирус гриппа | |
AR094725A1 (es) | Parvovirus 5a porcino, métodos de uso y vacuna | |
BR112022012731A2 (pt) | Anticorpo anti-ox40 e uso do mesmo | |
CO6382184A2 (es) | Proteinas fijadoras de receptores de interleukinas-21 | |
ECSP23029637A (es) | Virus de la diarrea epidémica porcina atenuado | |
AR051853A1 (es) | Vacuna para aumentar el crecimiento basada en epitopes neutralizantes | |
CL2023001846A1 (es) | Parapoxvirus modificado que tiene inmunogenicidad incrementada | |
BR112023024837A2 (pt) | Anticorpos anti-ccr8 | |
PH12020551876A1 (en) | Nucleic acid for treating mite allergy | |
MX2022002628A (es) | Proteinas de fusion y usos de las mismas. | |
DE50304603D1 (de) | Impfstoff gegen infektionen mit onkoviren, wie dem felinen leukosevirus der katze | |
MX2019011043A (es) | Nuevo compuesto derivado de la alulosa. | |
EA201990774A1 (ru) | Способ независимой от источника углерода селективной экспрессии белок-кодирующих последовательностей в клетке мицелиального гриба | |
AR122539A1 (es) | UNA VACUNA CONTRA EL SARS-CoV-2 | |
CO2022006965A2 (es) | Inhibidores de egfr | |
AR106453A1 (es) | Receptores celulares universales programables y métodos para usar los mismos |